Page 2 - Pharmaceutical Firms

Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

Pace of new product launches, filings key for Cipla's future growth

Strong India and Africa growth partially offset weakness in North America as Cipla focuses on respiratory launches and regulatory filings

India's next pharma leap will be built on smarter global regulations

A risk-based system allows regulators to pay attention where it matters most, while providing industry with predictability

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

Sun Pharma weighs multiple funding options for $12 billion Organon deal

The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt

Laurus Labs rallies 6%, hits record high post Q4 results; brokerages upbeat

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Sun Pharmaceutical acquires US-based Organon in $11.75 billion deal

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

Sun Pharma to acquire US drugmaker Organon in $11.75 billion all-cash deal

April 26 (Reuters) - India's Sun Pharmaceutical Industries ​will uy Organon & ​Co in an all-cash ‌deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.

Results preview: Pharma growth steady in Q4, but US drag weighs on margins

India's pharma and healthcare firms may post steady Q4 revenue growth, but weak US generics and rising costs are likely to keep margins under pressure

US pharma tariffs: CDMOs with innovator exposure likely to take a hit

Proposed US tariffs on patented drugs may pressure innovators to shift production locally, creating uncertainty for Indian CDMOs even as generics-led exports remain largely insulated

Trump imposes 100% tariff on patented drug imports; generics spared

The US has announced a 100 per cent tariff on patented pharma imports from countries like India without reshoring deals, aiming to boost local production, while generics have been exempted for now

Govt to intensify surveillance, audits against unauthorised GLP-1 sales

Online pharmacies, drug wholesalers under scanner; non-compliance may lead penalties, license cancellations

Acutaas Chemicals zooms 50% in 2 months, hits new high; here's why

In the past one month, the stock price of pharmaceuticals company has gained 15 per cent, as compared to 11 per cent decline in the BSE Sensex.

Uttar Pradesh to get major pharma boost with ₹2,500 crore investment

Uttar Pradesh is ramping up investments in pharma parks and medical device manufacturing to emerge as a major healthcare production hub in South Asia

Companies eye alternatives after CDSCO bans weight-loss drug ads

Firms may shift to doctor outreach, CME programmes and patient support initiatives as CDSCO bars advertising of GLP-1 drugs ahead of semaglutide patent expiry

Natco rallies 5%, nears 52-week high; what's driving pharma stock?

In the past four trading days, the stock price of Natco Pharma has surged 10 per cent after the company announced the launch of Pomalidomide Capsules (generic of Pomalyst) in the US market.

Emcure Pharmaceuticals soars 9% in weak market on huge volumes

Emcure Pharmaceuticals stock was quoting close to its 52-week high of ₹1,585.50 on Monday, and has surged up to 62% in the last one year.

Indian pharma market grows 11% in Feb as Mounjaro tops drug sales

The Indian pharmaceutical market posted 11% growth in February 2026, driven by strong therapy performance, while Mounjaro remained India's highest-selling drug by value for a fifth month

Indian CDMOs expand capacity as demand for complex drug work rises

Indian CDMOs are expanding manufacturing capacity and investing in advanced technologies as global pharma companies increasingly outsource complex drug development and manufacturing work

Sai Life hits record high in weak market; rebounds 5% from day's low

Supported by solid demand, disciplined execution, and capex programs progressing as planned, Sai Life management remains confident in sustaining positive growth momentum.